Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : The Trump Presidency -- Ignore unavailable to you. Want to Upgrade?

To: i-node who wrote (161103)	4/22/2020 5:43:29 PM
From: combjelly	Read Replies (1) \| Respond to of 363344

There is plenty of evidence. It happens in the studies. Some studies have been canceled because it was considered unethical to continue them. Granted, that is a word you don't seem familiar with. But...

To: i-node who wrote (161103)	4/22/2020 6:10:43 PM
From: Qone0	Read Replies (1) \| Respond to of 363344

“We performed a retrospective analysis of data from patients hospitalized with confirmed SARS-CoV-2 infection in all United States Veterans Health Administration medical centers until April 11, 2020,” the researchers explained. Some 97 patients had been treated with just hydroxycholoroquine, 113 were treated with hydroxycholoroquine and the antibiotic azithromycin and 158 received “standard supportive management” for COVID-19. The two primary outcomes analyzed in the study were death and the need for ventilation. About 28 percent who were given hydroxychloroquine plus usual care died, versus 11 percent of those getting routine care alone. About 22 percent of those getting the drug plus azithromycin died too, but the difference between that group and usual care was not considered large enough to rule out other factor. foxnews.com that could have affected survival.